52683-81-5

Usage

Uses

Used in Pharmaceutical Industry:
L-Proline, 4,4-difluoro(9CI) is used as a building block in drug design for its unique chemical properties and potential to enhance the activity and selectivity of pharmaceutical compounds. The incorporation of fluorine atoms can improve the pharmacokinetic and pharmacodynamic profiles of drugs, leading to more effective treatments.
Used in Chemical Research:
L-Proline, 4,4-difluoro(9CI) serves as a valuable research tool in chemical research, particularly in the study of protein structure and function. The altered chemical properties of L-Proline, 4,4-difluoro- (9CI) can provide insights into the role of L-proline in biological systems and contribute to the development of new therapeutic strategies.
Used in Drug Development:
L-Proline, 4,4-difluoro(9CI) is utilized in drug development to explore its potential as a therapeutic agent or as a component of novel drug candidates. L-Proline, 4,4-difluoro(9CI)'s unique structure may offer advantages in targeting specific biological pathways or improving the efficacy of existing drugs.
Further research is necessary to fully understand the potential uses and effects of L-Proline, 4,4-difluoro(9CI) in various fields, including its role in protein synthesis, its impact on biological functions, and its applications in drug design and development.

InChI:InChI=1/C5H7F2NO2/c6-5(7)1-3(4(9)10)8-2-5/h3,8H,1-2H2,(H,9,10)

Upstream product

• 156046-01-4 (5S)-7,7-difluoro-2,2-bis(trifluoromethyl)-1-aza-3-oxabicyclo<3.3.0>octan-4-one 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 148429-57-6 (S)-3,3-Bis-trifluoromethyl-dihydro-pyrrolo[1,2-c]oxazole-1,6-dione 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 

Downstream Products

• 203866-21-1 (2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4,4-difluoro-pyrrolidine-2-carboxylic acid 
• 1578153-20-4 (R)-6-((S)-2-carboxy-4,4-difluoro-pyrrolidin-1-ylmethyl)-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1578153-18-0 (S)-6-((S)-2-carboxy-4,4-difluoro-pyrrolidin-1-ylmethyl)-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1612854-24-6 C₁₉H₂₃BrF₂N₄O₅ 
• 1578153-96-4 (R)-6-((S)-2-carboxy-4,4-difluoro-pyrrolidin-1-ylmethyl)-4-(2,4-dichloro-phenyl)-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 1578153-71-5 6-((S)-2-carboxy-4,4-difluoro-pyrrolidin-1-ylmethyl)-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 1578153-88-4 (R)-6-((S)-2-carboxy-4,4-difluoro-pyrrolidin-1-ylmethyl)-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-1,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES

The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

PYRROLOTRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

Practical synthesis of Boc and Fmoc protected 4-fluoro and 4-difluoroprolines from trans-4-hydroxyproline

Boc-cis-4-fluoro-L-proline and 4-difluoro-L-proline, usable in classical peptide synthesis, were obtained in respectively 71% (3 steps) and 65% (4 steps) overall yields from the readily available trans-4-hydroxy-L-proline methyl ester. The corresponding fluorinated trans-isomer was isolated in 24% yield (5 steps). Transformation of Boc-protected compounds to their Fmoc-equivalents was performed in high yields.

Synthesis of (2S)-4,4-difluoroproline, (2S,4R)-4-fluoroproline and their derivatives from (S)-aspartic acid

Syntheses for (2S)-4,4-difluoroproline, (2S,4R)-4-fluoroproline and their derivatives are described starting from (S)-aspartic acid, using hexafluoroacetone as the protecting reagent and DAST as the fluorinating agent.